ArticleVascular and endovascular surgery2026
Perioperative and Long-Term Outcomes of Lower Extremity Revascularization in Patients With Malignancy.
Article in Vascular and endovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveCancer patients in general are thought to be poor candidates for lower extremity revascularization procedures due to hypercoagulability, potential need for chemotherapy, or multiple other cancer-related co-morbidities. While vascular surgeons may shy away from these patients, only one previous study we found has assessed the effect of this relationship on lower extremity bypass patency, and substantially worse outcomes were documented. Our study aims to quantify the risk of poor outcomes for lower extremity revascularization in a large sample of cancer patients, utilizing the TriNetX database.MethodsWithin the US cohort of 55 healthcare organizations in the TriNetX database, we identified 1419 patients diagnosed with either breast, prostate, colon, or non-small cell lung cancer of any stage and 60 609 patients without diagnosis of those cancers who had undergone either an open infra-inguinal bypass of any graft type or endovascular intervention on the infra-inguinal arteries from September 3, 2004 to September 3, 2024. Propensity score matching was conducted, which yielded 1413 patients analyzed in each group, and incidence of arterial thrombectomy, bypass revision, amputation, and arteriogram were recorded for each group at 30-day and 1-year time points. Secondary subgroup analyses were conducted within the cancer cohort to determine whether rates of the same outcomes listed above varied between open versus endovascular interventions.ResultsIn the primary analysis, there was no significant difference in any of the 4 outcomes between cancer patients and non-cancer patients. In the subgroup analysis, open bypass was found to have a significantly lower incidence of repeat arteriogram within 30 days as compared to endovascular intervention (3.62% vs 7.97%; risk ratio [RR], 0.455,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.